Asian Journal of Case Reports in Medicine and Health

Terbinafine Induced Stevens Johnson Syndrome Toxic Epidermal Necrolysis Overlap Syndrome

Aparna Matpathi *

CMR College of Pharmacy, Aditi Womens Hostel, Amba Towers, Street Number 14, Himayat Nagar, 500029, Hyderabad, Telangana, India.

Shagupta Shalu

CMR College of Pharmacy, Aditi Womens Hostel, Amba Towers, Street Number 14, Himayat Nagar, 500029, Hyderabad, Telangana, India.

Mokirala Niveditha

General Medicine, Gandhi Medical College, Aditi Womens Hostel, Amba Towers, Street Number 14, Himayat Nagar, 500029, Hyderabad, Telangana, India.

*Author to whom correspondence should be addressed.

---

Abstract

SJS-TEN overlap syndrome is a very rare but severe cutaneous adverse drug reaction that is caused by terbinafine administration. The patient was suffering from vulvovaginal for which she was consuming terbinafine which led to the occurrence of cutaneous eruptions, across the right and left lower limbs, face, upper limbs, chest, back, arms, and abdomen, affecting almost the entire body covering 10- 30% of the body surface which makes it to fall under the category of SJS-TEN overlap syndrome. Although considered safe terbinafine may lead to such severe adverse drug reactions, proper precautions need to be taken while prescribing it. Avoid the drug in patients with a history of any drug reactions. The main goal of this case report is to bring awareness among healthcare professionals, and to make them vigilant against such severe cutaneous drug reactions caused by terbinafine.

Keywords: Stevens-Johnson syndrome, toxic epidermal necrolysis, cytotoxic t-lymphocytes, terbinafine, body surface area

---

---

---

References

Suresh Kumar PN, Thomas B, Kumar K, Kumar S. Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TEN) overlap associated with carbamazepine use. Indian Journal of Psychiatry. 2005;47(2):121–123.

Available: https://doi.org/10.4103/0019-5545.55961

Oakley AM, Krishnamurthy K. Stevens Johnson Syndrome. [Updated 2022 Aug 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available:https://www.ncbi.nlm.nih.gov/books/NBK459323/

Frantz R, Huang S, Are A, Motaparthi K. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina. 2021;57(9):895.

Available:https://doi.org/10.3390/medicina57090895

Labib AM, Milroy C. Toxic Epidermal Necrolysis. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Available:https://www.ncbi.nlm.nih.gov/books/NBK574530/

Zimmerman D, Dang NH. Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions. Oncologic Critical Care. 2019;267–280.

Available: https://doi.org/10.1007/978-3-319-74588-6_195

Gronich N, Maman D, Stein N. et al. Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study. Am J Clin Dermatol. 2022;23:257–266.

Available: https://doi.org/10.1007/s40257-021-00661-0

Maxfield L, Preuss CV, Bermudez R. Terbinafine. [Updated 2022 Oct 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Available:https://www.ncbi.nlm.nih.gov/books/NBK545218

Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008;74: 238-240.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

Available: https://doi.org/10.1186/1750-1172-5-39

Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B. Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis. Indian journal of dermatology, 2017;62(4): 395–399.

Available:https://doi.org/10.4103/ijd.IJD_191_17

Lamichhane R, Pandey MR, Dhungana A, Lamsal A. Terbinafine-induced Toxic Epidermal Necrolysis in Pregnancy: A Case Report. JNMA; journal of the Nepal Medical Association, 2023;61(260):379–382.

Available:https://doi.org/10.31729/jnma.8116

Berthold Rzany MD, Maja Mockenhaupt MD, Wolfgang Gehring MD, Erwin Schopf MD. Stevens-Johnson syndrome after terbinafine therapy. Journal of the American Academy of Dermatology. 1994;30(3):509.

Available: https://doi.org/10.1016/S0190-9622(08)81961-5

Balai M, Meena M, Mittal A, Gupta LK, Khare AK, Mehta S. Cyclosporine in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Experience from a Tertiary Care Centre of South Rajasthan. Indian Dermatology Online Journal. 2020;12(1):116–122. Available:https://doi.org/10.4103/idoj.IDOJ_326_20